Synaptogenix Announces Phase 2b NIH Sponsored Alzheimer’s Disease Trial Update,

“Efficacy and safety continue to be our primary objectives in the clinical trials of Bryostatin to treat advanced AD patients.” About Synaptogenix, Inc., “Efficacy and safety continue to be our primary objectives in the clinical trials of Bryostatin to treat advanced AD patients.” About Synaptogenix, Inc., Read More

Scroll to Top